Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

被引：1

作者：

Murakami, H. ^{[1
]}

Yamamoto, N. ^{[1
,3
]}

Boku, N. ^{[2
]}

Yamazaki, K. ^{[2
]}

Yamamoto, N. ^{[1
,3
]}

Yamada, Y. ^{[4
]}

Yamada, K. ^{[3
]}

Puchalski, T. ^{[5
]}

Shin, E. ^{[6
]}

Tamura, T. ^{[3
]}

机构：

[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka 104, Japan

[2] Shizuoka Canc Ctr, Div Gastrointestinal Oncol & Endoscopy, Shizuoka 104, Japan

[3] Natl Canc Ctr, Div Internal Med, Tokyo, Japan

[4] Natl Canc Ctr, Div Gastrointestinal Oncol, Tokyo, Japan

[5] AstraZeneca, Res & Dev, Wilmington, DE USA

[6] AstraZeneca, Res & Dev, Osaka, Japan

来源：

EJC SUPPLEMENTS | 2008年 / 6卷 / 12期

关键词：

D O I：

10.1016/S1359-6349(08)72328-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：124 / 124

页数：1

共 50 条

[1] PHASE I STUDY OF CEDIRANIB, A VEGFR SIGNALING INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
Takahashi, T.
Yamamoto, N.
Boku, N.
Yamazaki, K.
Yamamoto, N.
Yamada, Y.
Yamada, K.
Shin, E.
Puchalski, T. A.
Tamura, T.
ANNALS OF ONCOLOGY, 2008, 19 : 159 - 159
[2] Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
Yamamoto, Noboru
Yamada, Yasuhide
Yamada, Kazuhiko
Nokihara, Hiroshi
Fujiwara, Yutaka
Hirata, Taizo
Yamamoto, Nobuyuki
Boku, Narikazu
Shin, Eisei
Tamura, Tomohide
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3417S - 3418S
[3] Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
Noboru Yamamoto
Tomohide Tamura
Nobuyuki Yamamoto
Kazuhiko Yamada
Yasuhide Yamada
Hiroshi Nokihara
Yutaka Fujiwara
Toshiaki Takahashi
Haruyasu Murakami
Narikazu Boku
Kentaro Yamazaki
Thomas A. Puchalski
Eisei Shin
Cancer Chemotherapy and Pharmacology, 2009, 64 : 1165 - 1172
[4] Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
Yamamoto, Noboru
Tamura, Tomohide
Yamamoto, Nobuyuki
Yamada, Kazuhiko
Yamada, Yasuhide
Nokihara, Hiroshi
Fujiwara, Yutaka
Takahashi, Toshiaki
Murakami, Haruyasu
Boku, Narikazu
Yamazaki, Kentaro
Puchalski, Thomas A.
Shin, Eisei
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1165 - 1172
[5] Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
Joleen M. Hubbard
Jun Yin
Erin L. Schenk
Rui Qin
Joel M. Reid
Carrie Strand
Jack Fiskum
Michael Menefee
Grace Lin
L. Austin Doyle
Percy Ivy
Charles Erlichman
Alex Adjei
Paul Haluska
Brian A. Costello
Investigational New Drugs, 2022, 40 : 115 - 123
[6] Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
Hubbard, Joleen M.
Yin, Jun
Schenk, Erin L.
Qin, Rui
Reid, Joel M.
Strand, Carrie
Fiskum, Jack
Menefee, Michael
Lin, Grace
Doyle, L. Austin
Ivy, Percy
Erlichman, Charles
Adjei, Alex
Haluska, Paul
Costello, Brian A.
INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 115 - 123
[7] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
Zhu, Mojun
Molina, Julian R.
Dy, Grace K.
Croghan, Gary A.
Qi, Yingwei
Glockner, James
Hanson, Lorelei J.
Roos, Michelle M.
Tan, Angelina D.
Adjei, Alex A.
INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1755 - 1762
[8] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
Mojun Zhu
Julian R. Molina
Grace K. Dy
Gary A. Croghan
Yingwei Qi
James Glockner
Lorelei J. Hanson
Michelle M. Roos
Angelina D. Tan
Alex A. Adjei
Investigational New Drugs, 2020, 38 : 1755 - 1762
[9] Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors
Niwakawa, Masashi
Yamaguchi, Raizo
Onozawa, Yusuke
Yasui, Hirofumi
Taku, Keisei
Naito, Tateaki
Akinaga, Shiro
Boku, Narikazu
Yamamoto, Nobuyuki
CANCER SCIENCE, 2013, 104 (08) : 1039 - 1044
[10] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
Hideki Ueno
Shunsuke Kondo
Shusuke Yoshikawa
Koichi Inoue
Valérie Andre
Masaomi Tajimi
Haruyasu Murakami
Investigational New Drugs, 2018, 36 : 647 - 656

← 1 2 3 4 5 →